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Moutan Cortex, a widely used traditional Chinese medicine for the treatment of various
diseases, is the root bark of Paeonia suffruticosa Andrews (Paeoniaceae). Most of the
pharmacological investigations of Moutan Cortex have been addressed to its central nervous
system activities, anti-oxidative and sedative actions. Otherwise, there are few reports about the
active compounds with anti-inflammatory activity of Moutan Cortex. The aim of the present
study was to screen and identify bioactive compounds with anti-inflammatory effect from
Moutan Cortex. With the aid of preparative high performance liquid chromatography (HPLC)
technique, ethyl acetate and ethanol extract of Moutan Cortex were isolated into twenty-two
fractions. Bioactivities of these fractions were evaluated by measuring expression of tumor
necrosis factor-a (TNF-a) in rat synoviocytes subjected to interleukin-1b (IL-1b). Eight
compounds were isolated from six active fractions and identified by HPLC/MS
n. Purified
compounds, paeoniflorin, paeonol and pentagalloylglucose resulted in dose-dependent
inhibition of TNF-a synthesis and IL-6 production in synoviocytes treated with proinflamma-
tory mediator. These results suggested that paeonol, paeoniflorin, glycosides and pentagalloyl-
glucose contribute to the anti-inflammatory effect of Moutan Cortex.
Keywords: moutan cortex–proinflammatory mediator–screening trials–synoviocytes–tumor
necrosis factor (TNF)–IL-6
Introduction
Moutan Cortex, the root bark of Paeonia suffruticosa
Andrews (Paeoniaceae), has been used extensively as a
traditional Chinese medicine (TCM) for treating various
diseases in China and in other eastern Asian countries.
Moutan Cortex is used to treat a plethora of disease
classes such as atherosclerosis, infection and inflamma-
tion, among many others. A variety of compounds, such
as paeonoside, paeonolide, apiopaeonoside, paeoniflorin,
oxypaeoniflorin, benzoyloxypaeoniflorin, benzoylpaeoni-
florin, paeonol and sugars, etc. have been identified and
determined in Moutan Cortex (1). Many clinical and
experimental studies have reported that crude extracts of
Moutan Cortex have therapeutic effects on ischemic heart
diseases (2,3). Further, recent pharmacological studies
revealed that Moutan Cortex can inhibit the production
of reactive oxygen species (ROS) (4) and some paeonol
glycosides exhibited radical scavenging effects (5).
Matsuda H et al. (6) reported the isolation of five
paeonol glycosides and their radical scavenging effects.
The synoviocytes cells are important part of joint tissue
and can produce pro-inflammatory mediators that are key
players in pathophysiology of arthritis. The occurrence of
inflammatory reactions in the synovial membrane has been
demonstrated as the initial motive of temporomandibular
disorders (TMD) (7), similar to the pathologic changes of
osteoarthritis (OA) and rheumatoid arthritis (RA) (8,9).
It has been reported that extracts from the roots of Paeonia
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properly cited.lactiflora Pall, another medicinal herb with analogous
chemical composition of Moutan Cortex, can possess anti-
inflammatory effects on arthritis rats by modulating the
pro-inflammatory mediators production and change the
ultrastructure of synoviocytes (10). However, the bioactive
compounds of Moutan Cortex, which are potential to
confer inflammatory mediator in cellular models, have not
yet been evaluated.
Many in vitro cell models including tumor cell lines and
macrophages have been used to screen herbal extracts for
anti-inflammatory activity. An in vitro model, which can
appropriately represent the joint tissue and allow
monitoring of physiological markers in response to
treatment agents, has been established in previous
report (11). The aim of the present study was to screen
and identify active compounds from Moutan Cortex with
anti-inflammatory action. Fractions from the ethyl-
acetate and ethanol extracts of Moutan Cortex were
obtained by preparative high performance liquid chro-
matography (HPLC) and assayed for their abilities of
reducing expression of tumor necrosis factor-a (TNF-a).
Eight compounds in six fractions with significant activity
were identified. Dose-dependent effects of three purified
compounds, paeoniflorin, paeonol, and pentagalloylglu-
cose have been studied.
Methods
Plant Materials and Reagents
Moutan Cortex was purchased from Hangzhou
Traditional Chinese Medicine Company (Hangzhou,
China). The crude sample was authenticated morpholo-
gically by Assistant Prof. Heqing of Zhejiang University.
A voucher specimen has been deposited in the herbaria
(Department of Chinese Medicine Sciences &
Engineering, Zhejiang University, China), under the
acquisition number of DP-1L.
Ethylacetate (EtOAc), methanol and ethanol were of
analytical grade from Hangzhou Reagent Company
(Hangzhou, China). Acetonitrile for HPLC analysis was
of HPLC grade from E. Merck (Darmstadt, Germany).
Water for HPLC analysis was purified by a Milli-Q
academic water purification system (Milford, MA, USA).
For cell culture, DMEM medium and collagenase II were
purchased from Gibco (CA, USA); trypsin was obtained
from Sigma (St. Louis, MO USA); fetal calf serum was
purchased from HyClone (Logan, USA).
Extraction and Isolation
Air-dried plant material (250g) were crushed and
macerated consecutively with the mixture of ethylacetate
(EtOAc) and ethanol (v:v 1:1) and 70% ethanol solution
for 1day. The extract obtained was filtered and the
solvent removed in vacuum and two fractions were
obtained: extract A with lower polarity and extract B
with higher polarity. The yield ratio was 8.6% and
16.4%, respectively.
The extract A was transferred into a silica gel column
and chromatographed using a step gradient solvent
system starting with petroleum ether, chloroform and
ending with methanol. The elution of a mixture of
chloroform and methanol (10:1) were collected and dried
in vacuum to get extract C. The extract B was subjected
to a silica gel column using a step gradient solvent system
with methanol aqueous solutions (5%, 70% and 100%)
and the elution of 70% methanol was collected to obtain
extract D.
Further separations of extract C and extract D were
performed on a Hanbang RP-18 semi-preparative column
(5mm, 250 10mm; Hanbon Sci. & Tech, China) and
Agilent 1100 series preparative HPLC system
(Waldbronn, Germany) equipped with a binary high-
pressure mixing pump and fraction collector. The flow
rate was 3mL/min and the detection wavelength of the
diode array detector was set at 230nm. For extract C, the
following gradient profile with water (solvent A) and
acetonitrile (solvent B, E. Merck) was used: solvent B,
0–40min, 20–80%; 40–50min, 80–95%. Nine different
fractions were collected according to the time schedule as
shown in Table 1. Extract D was separated in the same
manner with a gradation: solvent B, 0–8min, 10–19%;
8–50min, 19–35%; 50–65min, 35–95%; 65–70min, 95%.
Thirteen fractions were obtained.
Identification of Active Compounds
Preliminary phytochemical investigations of fractions
were carried out by HPLC/Ms
n. The chromatographic
separation was performed on a Lichrospher C18 column
(5mm, 4.6 250mm, Hanbang Science & Technology)
with an Agilent 1100 HPLC system (Waldbroonn,
Germany) equipped with a quaternary pump, vacuum
degasser, autosampler, diode-array detector, column
heater-cooler and ChemStation system. A LCQ DECA
XP
plus mass spectrometer (Thermo Finnigan, San Jose,
CA, USA) equipped with an ESI interface and an ion
Table 1. Collection procedure of fractions by preparative-HPLC; the number in the table represents the started time of collection for each fraction
N o . 1 2 34567891 0 1 1 1 2 1 3
extract C 4.0 7.6 9.7 14.2 18.4 21.8 26.5 30.3 35.5 / / / /
extract D 4.0 7.7 10.7 15.8 18.8 23.2 27.4 33.1 40.2 44.4 48.5 58.0 67.0
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MS
n. The column temperature was set at 30 C. Detection
was at 230nm and spectrograms were recorded between
200 and 400nm at the apex of each peak.
Pure chemicals of paeoniflorin and paeonol were
purchased from the National Institute for the Control
of Pharmaceutical and Biological Products (Beijing,
China). Compounds in the samples were identified by
comparison of the retention time and spectrum for each
peak with the corresponding standard. By comparison of
molecular weight, UV absorbance and mass fragments
information with those of published data, a number of
compounds can be tentatively identified.
Cultured Synoviocytes and In Vitro Screening Model
Synoviocytes were isolated from the double condyle of
rat temporomandibular joint and cultured according to a
described procedure with minor modifications (12). The
use of animals was in accordance with Guideline for the
Care and Use of Laboratory Animals of Zhejiang
University. Briefly, the double condyles of 3 months
old Sprague–Dawley rats (obtained from the Zhejiang
Center of Laboratory Animals, China) were excised, the
synovium of bilaminar zone (BZ) were separated, washed
extensively with phosphate buffered saline (PBS), then
minced and digested three times by 0.125% trypsin and
0.05% collagenase II at 37 C for 30min. Synoviocytes
were seeded into a cover plate, incubated in DMEM
(Gibco, Grand Island, NY, USA) supplemented with l-
glutamine, streptomycin, penicillin and 10% fetal calf
serum at 37 C in a humidified atmosphere containing 5%
CO2. A pre-treatment of fractions on synoviocytes was
performed to evaluate cell viability through trypan blue
dye and morphological observation.
To evaluate anti-inflammatory effects of different
fractions, synoviocytes were seeded onto 24-well plates
at 1 10
5 cells/well. Synoviocytes were next incubated
with control media alone or with fraction (10
 5gmL
 1)
1h before reincubation with 10ng mL
 1 interleukin-1b
(IL-1b) or control media alone for 1h. Supernatant
medium samples were taken for the detection of TNF-a
concentration by enzyme-linked immunosorbent assay
(ELISA) (Biosource International, Camarillo, CA, USA).
A commercial rat-specific IL-6 ELISA kit (Quantikine,
R&D Systems) was used to quantify IL-6. The effective-
ness of tested fractions was determined by comparing
TNF-a concentration in treated group to the untreated
cells.
Statistics
Results were expressed as mean S.E.M. Statistical
analysis between groups was carried out by one-way
analysis of variance and the Newman–Keuls Student
t-test. The level of significance was chosen as P50.05.
Results
Anti-Inflammatory Effects of Fractions
The fractions obtained were combinations of a few
compounds with similar chemical properties. Evaluation
of cell viability indicated that incubation of synoviocytes
with fractions of Moutan Cortex for 1day at concentra-
tion of 10gmL
 1 does not reduce the percent of viable
cells. There was no significant difference in cell number
between treated and untreated control cells (P40.05).
The anti-inflammatory activities of totally 22 fractions
were assayed in IL-1b stimulated synoviocytes.
It has been found that the level of TNF-a in synoviocytes
incubated with pro-inflammatory mediators was
significantly increased in comparison with the untreated
control. It was observed that four adjacent fractions
from extract C, i.e. fraction C-3, C-4, C-5, C-6,
exhibited similar efficacy on suppressing the release
of TNF-a. Additionally, two fractions in extract D,
D-3 and D-10, significantly affect production of
TNF-a (Fig. 1).
Identification of Compounds in Active Fractions
To illustrate chemical composition of those bioactive
fractions, the major constituents were identified by
HPLC/MS
n. Five paeonol glycosides including paeonol,
paeoniflorin and its derivatives in extract C and
Figure 1. Inhibition of tumor necrosis factor-a (TNF-a) synthesis by
fractions of Moutan Cortex. Synoviocytes were incubated with control
medium alone or (10mgm L
 1 of fraction for 1h) before the addition of
control medium alone or 10ng mL
 1 interleukin-1b (IL-1b). The cells
were reincubated for (24h at 37 C, 5% carbon dioxide) and the secreted
TNF-a concentration were measured with ELISA. Compared with
control group (*P50.05, **P50.01, n¼3).
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1,2,3,4,6-pentagalloylglucose in extract D were identified.
Major constituents of active fractions were further
isolated by preparative HPLC and purified. Some
purified compounds, such as paeonol and paeoniflorin
were identified by comparing MS/MS
n data with
standard samples. Other compounds, including pentagal-
loylglucose, galloylpaeoniflorin, benzoylpaeoniflorin, ben-
zoyl- oxypaeoniflorin, mudanpioside B and mudanpioside
H were identified by comparing MS
n and NMR data
with previously reported data. Major compounds of
those fractions are listed in Table 2 and their structures
are shown in Fig. 2.
Dose-Dependent Effect of Purified Compounds
on TNF-a Level
Anti-inflammatory effects of three major components,
paeonol, paeoniflorin and pentagalloylglucose at concen-
trations ranging from 6.1 to 200mM were tested on the
above cell model. As shown in Fig. 3, in comparison of
the negative control (untreated synoviocytes), TNF-a
level in control group (IL-1 treated synoviocytes)
significantly increased (P50.01). Paeonol, paeoniflorin
and pentagalloylglucose can significantly suppress the
increase of TNF-a level in dose-dependent manner
compared with the control group. The ratio of TNF-a
concentration in treated well to untreated well was used
Table 2. HPLC-DAD-MS
n data of identified compounds in active fractions
Fraction M.W. MS
n UV (nm) Compounds
C-3 480 449 [M-H-CH2O] 327 [M-H-CH2O-(Benzoic acid)]
165[M-H-CH2O-(Benzoic acid)-Glucose]
195, 235 Paeoniflorin
C-4 616 585 [M-H-CH2O 447[M-H-CH2O-(p-hydroxybenzoic acid)] 215, 270 Mudanpioside H
C-4 632 491 [M-H-C6H5COOH] 313 [M-H- C6H5COOH- gallic acid] 230 Galloylpaeoniflorin
C-5 600 569 [M-H-CH2O] 477 [M-H-CH2O-(Benzoic acid)] 230, 260 Benzoyloxypaeoniflorin
C-5 584 461 [M-H-(Benzoicacid)]







C-6 166 149 [MþH-H2O]
þ 121 [MþH-H2O-CO]
þ 230, 280 Paeonol
D-3 464 301 [M-H- C6H10O5] 215, 275 Mudanoside B
D-10 940 769 [M-H-gallic acid]





Figure 2. Structures of active compounds.
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pounds. Paeonol decreased the level of TNF-a with
maximum inhibition (57%) at a concentration of 200mM,
whilst pentagalloylglucose achieved better anti-inflamma-
tory effect (45%) at the same concentration. Paeoniflorin
exhibited a maximum inhibition (72%).
Dose-Dependent Effect of Purified Compounds
on IL-6 Level
IL-6 is one of the most potent cytokines that promote
inflammatory events through expansion and activation of
T cells, differentiation of B cells and induction of the
acute phase response (13). Several cytokines including
TNF-a, IL-1 can stimulate the synthesis of IL-6 (14,15).
To examine anti-inflammatory effects of purified com-
pounds, effects of paeonol, paeoniflorin and pentagal-
loylglucose on the production of IL-6 in IL-1b stimulated
synoviocytes were studied. As shown in Fig. 4, paeonol,
paeoniflorin and pentagalloylglucose significantly
decreased IL-6 level in dose-dependent manner.
In summary, the present data illustrated that the
purified compounds were bioactive compounds of
Moutan Cortex with anti-inflammatory activity.
Discussion
In the study on anti-anaphylactic activity of paeonol by
Kim et al. (16), paeonol exhibited significant regulation
on the release of TNF-a. Although anti-inflammatory
effect of paeonol on synoviocytes has not been reported,
a recent study reveals that paeonol dose-dependently
inhibited TNF-a and IL-1b formation in the rat paw
exudates after carrageenan injection (17). Chun et al.
(18) also reported anti-inflammatory activity of the
methanol extract of Moutan Cortex in RAW264.7 cells
after treatement with, lipopolyssacharide (LPS) and
suggested that the anti-inflammatory effects were
induced through the inhibition of iNOS and COX-2
expression by suppressing the phosphorylation of I-kBa
and the activation of NF-kB. Therefore, the possible
mechanisms by which paeonol exerts its anti-inflamma-
tory effect may be associated with decreased production
of pro-inflammatory cytokines, NO and increased
production of IL-10. Total glucosides of paeony
(TGP) has been proven to be an anti-inflammatory
extract by modulating phosphorylation of MAPKs from
synoviocytes (10). Paeoniflorin and its derivatives such
as benzoylpaeoniflorin and galloylpaeoniflorin are major
components of TGP. Thus, it suggests that the possible
mechanism for anti-inflammatory effect of paeoniflorin
may be attributed to the activation of the MARKs
cascades and other transcription factors.
Pentagalloylglucose is a newly found component with
anti-endotoxin effect both in endotoxemic mice and
rats. The reduction of the endotoxin levels in rats
tightly associated with the TNF-a level (19). Therefore,
pentagalloylglucose might suppress TNF-a release in a
dose dependent manner.
In recent years, it has been proven that extracts or
compounds from many herbs may provide a safe and
effective adjunctive therapeutic approach for the treat-
ment of osteoarthritis and RA (20). Tohda et al. (21)
has compared anti-inflammatory activities of six differ-
ent species of Curcuma herbs in adjuvant arthritis model
mice and found a most effective specie. Thus, it can be
Figure 3. Dose-dependent inhibition of TNF-a synthesis induced by
paeonol ( ), paeoniflorin (œ), and pentagalloylglucose (g)o n
synoviocytes. Bars represent standard deviations, n¼4. The percentage
of inhibition rate was calculated as follows: inhibition rate
[(%)¼100 (TNF-a level in treated well/TNF-a level in the control
well)]. TNF-a level in negative control (untreated synoviocytes) and
control (IL-1 treated synoviocytes) was expressed as bar graph.
Comparing with control group, *P50.05, **P50.01.
Figure 4. Dose-dependent inhibition of IL-6 level induced by paeonol,
paeoniflorin and pentagalloylglucose in the range of (6.25–200mM) on
IL-1 stimulated synoviocytes. TNF-a level in negative control
(untreated synoviocytes) and control (IL-1 treated synoviocytes) was
also expressed. Bars represent standard deviations (n¼6). Comparing
with control group, *P50.05, **P50.01.
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therapy of temporomandibular syndrome. Traditionally,
temporomandibular disorder (TMD) is treated with
conservative therapy. Some alternative and complemen-
tary therapy for TMD patients has also been intro-
duced, including intra-articular injection of superoxide
dismutase (SOD) (22) and sodium hyaluronate (SH)
(23). It has been reported that extracts of Moutan
Cortex and paeonol can increase SOD activity in
ischemic brain tissue (24) and cultured synoviocytes
(25). The chemical and biological investigations carried
out in this work lead to the detection of several active
compounds in Moutan Cortex as inhibitor of pro-
inflammatory mediator. Though the exact mechanism of
action responded for the anti-inflammatory effects of
those compounds still need further investigation, the
result of present study offers a new way for the
treatment of TMD.
To our knowledge, bioavailabilities of some identified
active compounds are not good. However, Liu et al. (26)
suggested that poor bioavailability of paeoniflorin can be
significantly increased by other chemicals such as
sinomenine and verapamil. It also reported that absorp-
tion of paeoniflorin after oral administration of the two
herbal formulations was significantly greater than that
after oral administration alone (27). Therefore, bioavail-
ability of the isolated compounds and their interaction on
pharmacokinetics should be further evaluated in our
future study to help design rational dosage regimens. It
can be expected that new agents can be developed from
extracts and active compounds with anti-inflammatory
effect of Moutan Cortex for patients with temporoman-
dibular dysfunction who fail to respond to conservative
treatment.
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